As more cancer survivors live longer, the challenges increase for those responsible for coordinating care among primary care providers, specialists, and oncologists. The concept of survivorship continues to evolve to include life long after cancer treatment, according to updated guidelines from the National Comprehensive Cancer Network.
Germline testing at diagnosis, along with tumor testing, have the potential to identify candidates for investigational poly (ADP-ribose) polymerase (PARP) inhibitors, and updated guidelines call for their expanded use.
CancerIQ is reducing barriers that make it difficult to utilize genetic testing to predict or pre-empt a patient’s cancer diagnosis, explained Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.
More and more, care is moving into the home with new tools and technologies that can monitor patients, but this raises the question of how to handle this new data, said John D. Halamka, MD, MS, of Beth Israel Deaconess Health System.
Multigene testing provides a lot of information that providers have to be familiar with in order to adequately explain it to their patients, said John H. Ward, MD, Huntsman Cancer Institute at the University of Utah.
CMS’ proposal that patients be enrolled in a clinical trial or registry to get Medicare coverage for chimeric antigen receptor (CAR) T-cell therapies will help improve access, for the most part, but there is the risk that some organizations will choose not to offer this treatment, said John W. Sweetenham, MD, of Huntsman Cancer Institute at the University of Utah.
Guideline updates discussed Thursday at the 2019 National Comprehensive Cancer Network Annual Conference reflect recent practice-changing clinical trials involving pembrolizumab and chemotherapy.
A diverse panel of representatives from different practice models provided insights into what has worked for them and what has not in trying to improve cancer care. The discussion took place in Washington, DC, at the Association of Community Cancer Centers
A panel during the opening day of the 2019 National Comprehensive Cancer Network Annual Conference examined the recent process for National Coverage Determination for chimeric antigen receptor (CAR) T-cell therapy and what it means for the future of innovative treatments.
Healthcare futurist Joe Flower discusses the need to look at the bigger picture when trying to change the way we deliver cancer care.
Healthcare futurist Joe Flower opened up the Association of Community Cancer Centers 45th Annual Meeting and Cancer Center Business Summit, held March 20-22 in Washington, DC, with a vision of a healthcare system that provides better quality care at a lower cost that is more easily accessible for all stakeholders.
While there is currently a presence of technology in healthcare, the future holds much more promise, said Allen Lichter, MD, FASCO, senior partner of TRG Healthcare.
Value-based insurance design (VBID) aligns patient cost sharing with the value of clinical services, so that patients pay less for high-value services and more for unnecessary, low-value services. While there has been increased interest in VBID, with CMS expanding the VBID demonstration in Medicare Advantage to all 50 states, the situation on the state exchanges is different: The plan has to be cost neutral, so in order to remove cost sharing for high-value services, cost sharing has to increase for other, low-value services.
The INFINITY trial, presented at the 68th Scientific Session of the American College of Cardiology, tracked hypertension, brain lesions, and gait in groups of older seniors who had their systolic blood pressure managed to either 130 mm Hg or 145 mm Hg. Results showed significant differences in brain lesions between the 2 groups after 3 years.
New results presented at the American College of Cardiology's 68th Annual Scientific Session find a high-dose fish oil pill reduced the risk for first and future cardiovascular events among patients taking statins by 30%. The early results grabbed headlines last fall in part because researchers aren't entirely sure how the capsule works.
New findings show reduced hospitalizations for a wide group of patients with heart failure. For high-risk patients with reduced ejection fraction, the drug appears to cut deaths, but more studies will answer these questions.
More than a decade after an FDA mandate for cardiovascular outcomes trials, cardiologists say insights gained on how 2 new drug classes affect heart failure in diabetes should be used to prevent complications. Several sessions at the 68th Scientific Session of the American College of Cardiology addressed this topic.
The AUGUSTUS trial was designed to guide clinicians in treating patients with complex heart problems who are typically left out of other clinical trials. Results were presented Sunday at the 68th Scientific Session of the American College of Cardiology, held in New Orleans, Louisiana.
The joint guidelines from the American College of Cardiology and the American Heart Association call on clinicians to pay more attention to social determinants of health. They were announced Sunday at the 68th Scientific Session of the American College of Cardiology in New Orleans, Louisiana.
While the high price of drugs is an issue, what is really important is the actual cost patients are faced with at the pharmacy counter, said Ted Okon, executive director of the Community Oncology Alliance, and Daniel Klein, president and executive director of the Patient Access Network Foundation, at the University of Michigan Center for Value-Based Insurance Design (V-BID), V-BID Summit.
A session at the 68th American College of Cardiology Scientific Session continues the ongoing debate whether a CMS reimbursement model has contributed to rising mortality in patients with heart failure.
The 68th American College of Cardiology Scientific Session and Exposition opens with a study that suggests the Apple Watch can detect atrial fibrillation with a reasonable degree of accuracy, giving people an opportunity to get in touch with their doctor before a serious event like a stroke.
In recent years, the big news on the first day of the American College of Cardiology (ACC) Scientific Session and Exposition has involved a therapy—usually an expensive cholesterol drug with a name almost no one could pronounce: proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. This year, it's tech, and an easy-to-pronounce name: Apple.
The concept of value is a well-known topic among health policy experts, the payer community, and policy makers, but patients do not necessarily have the same idea of what value means. When discussions about removing low-value care from the system to save money come up, patients might get the wrong idea of what is going on and why.
There are similarities between the challenges of accessing good cancer care in rural areas of the United States and Rwanda, such as poverty, transportation, and lack of routine care, said Lawrence N. Shulman, MD, director of the Center for Global Cancer Medicine at the Abramson Cancer Center, and professor of Medicine at the Hospital of the University of Pennsylvania.
The Virginia Center for Health Innovation (VCHI) is receiving a $2.2 million grant from Arnold Ventures to launch a 3-year statewide pilot to reduce the use of low-value care in the state of Virginia.
There has always been interest in bundled payments, and now the industry is moving toward implementing more, explained Scott Hewitt, vice president, payment strategy and innovation, UnitedHealthcare.
Despite a patient's vigilance, there is an unpredictable risk of an accidental reaction from an exposure, explained Brian Vickery, MD, associate professor of pediatrics at Emory University and director of the Food Allergy Center, Children’s Healthcare of Atlanta.
There is a lot involved if an accountable care organization (ACO) decides to switch from Medicare Shared Savings (MSSP) to Medicare Advantage, but Medicare Advantage offers more benefit design flexibility, explained Kim Kauffman, MPH, vice president of value-based care at Summit Medical Group.
Researchers are encouraged by a set of peanut allergy immunotherapy data released Sunday at the 2019 American Academy of Allergy, Asthma & Immunology Annual Meeting, but they said that more discoveries are needed to understand which treatment might be best suited for patients.